Document:

EX-4.2

Table of Contents

 Exhibit 4.2 

EXECUTION  
 EIDOS
THERAPEUTICS, INC. 
 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

Table of Contents

 Table of Contents 

 

									
	 	 	 	 	 	  	Page	 
	 1.
	 	DEFINITIONS	  	 	1	 
			
	 2.
	 	REGISTRATION RIGHTS	  	 	4	 
		 	2.1	 	Demand Registration	  	 	4	 
		 	2.2	 	Company Registration	  	 	5	 
		 	2.3	 	Underwriting Requirements	  	 	6	 
		 	2.4	 	Obligations of the Company	  	 	7	 
		 	2.5	 	Furnish Information	  	 	8	 
		 	2.6	 	Expenses of Registration	  	 	8	 
		 	2.7	 	Delay of Registration	  	 	9	 
		 	2.8	 	Indemnification	  	 	9	 
		 	2.9	 	Reports Under Exchange Act	  	 	11	 
		 	2.10	 	Limitations on Subsequent Registration Rights	  	 	12	 
		 	2.11	 	“Market Stand-off” Agreement	  	 	12	 
		 	2.12	 	Restrictions on Transfer	  	 	13	 
		 	2.13	 	Termination of Registration Rights	  	 	14	 
			
	 3.
	 	INFORMATION AND OBSERVER RIGHTS	  	 	14	 
		 	3.1	 	Delivery of Financial Statements	  	 	14	 
		 	3.2	 	Inspection	  	 	15	 
		 	3.3	 	Observer Rights	  	 	15	 
		 	3.4	 	Termination of Information and Observer Rights	  	 	16	 
		 	3.5	 	Confidentiality	  	 	16	 
			
	 4.
	 	ADDITIONAL COVENANTS	  	 	17	 
		 	4.1	 	Insurance	  	 	17	 
		 	4.2	 	Employee Agreements	  	 	17	 
		 	4.3	 	Employee Stock	  	 	17	 
		 	4.4	 	Board and Observer Matters	  	 	17	 
		 	4.5	 	Successor Indemnification	  	 	17	 
		 	4.6	 	Indemnification Matters	  	 	18	 
		 	4.7	 	Right to Conduct Activities	  	 	18	 

  
 -i- 

Table of Contents

 Table of Contents 

(continued) 
  

									
	 	 	 	 	 	  	Page	 
		 	 4.8
	 	 FCPA
	  	 	19	 
		 	4.9	 	Termination of Covenants	  	 	19	 
			
	 5.
	 	 RIGHTS OF FIRST REFUSAL
	  	 	20	 
		 	5.1	 	Subsequent Offerings	  	 	20	 
		 	5.2	 	Exercise of Rights	  	 	20	 
		 	5.3	 	Issuance of Equity Securities to Other Persons	  	 	20	 
		 	5.4	 	Sale Without Notice	  	 	21	 
		 	5.5	 	Termination and Waiver of Rights of First Refusal	  	 	21	 
		 	5.6	 	Assignment of Rights of First Refusal	  	 	21	 
		 	5.7	 	Excluded Securities	  	 	21	 
			
	 6.
	 	 MISCELLANEOUS
	  	 	21	 
		 	6.1	 	Successors and Assigns	  	 	21	 
		 	6.2	 	Governing Law	  	 	22	 
		 	6.3	 	Counterparts	  	 	22	 
		 	6.4	 	Titles and Subtitles	  	 	22	 
		 	6.5	 	Notices	  	 	22	 
		 	6.6	 	Amendments and Waivers	  	 	22	 
		 	6.7	 	Severability	  	 	23	 
		 	6.8	 	Aggregation of Stock	  	 	23	 
		 	6.9	 	Additional Investors	  	 	23	 
		 	6.10	 	Entire Agreement	  	 	23	 
		 	6.11	 	Dispute Resolution	  	 	24	 
		 	6.12	 	Delays or Omissions	  	 	24	 

 Schedule A – Investors 

Schedule B – Key Holders 

  
 -ii- 

Table of Contents

 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

THIS AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 29th day of March, 2018, by and among Eidos
Therapeutics, Inc. a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”, and each of the
stockholders listed on Schedule B hereto, each of whom is referred to herein as a “Key Holder” and any Additional Purchaser (as defined in the Purchase Agreement) that becomes a party to this Agreement in accordance
with Section 5.9 hereof. 
 RECITALS 

WHEREAS, certain of the Investors (the “Existing Investors”) hold shares of the
Company’s Series Seed Preferred Stock and/or shares of Common Stock issued upon conversion thereof and possess registration rights, information rights, rights of first offer, and other rights pursuant to an Investors’ Rights Agreement
dated as of April 5, 2016 between the Company and such Investors (the “Prior Agreement”); and 

WHEREAS, the Existing Investors are holders of at least a majority of the Registrable Securities of the
Company (as defined in the Prior Agreement), and desire to amend and restate the Prior Agreement in its entirety and to accept the rights created pursuant to this Agreement in lieu of the rights granted to them under the Prior Agreement; and 

WHEREAS, certain of the Investors are parties to that certain Series B Preferred Stock Purchase Agreement
of even date herewith between the Company and certain of the Investors (the “Purchase Agreement”), under which certain of the Company’s and such Investors’ obligations are conditioned upon the execution and delivery
of this Agreement by such Investors, Existing Investors holding at least a majority of the Registrable Securities, and the Company;  

NOW, THEREFORE, the Existing Investors hereby agree that the Prior Agreement shall be
amended and restated, and the parties to this Agreement further agree as follows: 
 1.
DEFINITIONS. For purposes of this Agreement: 
 1.1
“Affiliate” means, with respect to any specified Person, any other Person who, directly or indirectly, controls, is controlled by, or is under common control with such Person, including without limitation any general partner,
managing member, officer or director of such Person or any venture capital, private equity or similar investment fund now or hereafter existing that is controlled by one or more general partners or managing members of, or shares the same management
company with, such Person; with respect to any Person that is an investment fund advised or sub-advised by a registered investment adviser, any other investment fund advised or
sub-advised by the same registered investment adviser. 
 1.2 “Common
Stock” means shares of the Company’s common stock, par value $0.001 per share. 

Table of Contents

 1.3 “Damages” means any loss, damage, claim or liability (joint or
several) to which a party hereto may become subject under the Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, damage, claim or liability (or any action in respect thereof) arises out of or is based upon:
(i) any untrue statement or alleged untrue statement of a material fact contained in any registration statement of the Company, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto;
(ii) an omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading; or (iii) any violation or alleged violation by the indemnifying party (or any
of its agents or Affiliates) of the Securities Act, the Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act, or any state securities law. 

1.4 “Derivative Securities” means any securities or rights convertible into, or exercisable or exchangeable for
(in each case, directly or indirectly), Common Stock, including options and warrants. 
 1.5 “Exchange Act”
means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder. 
 1.6
“Excluded Registration” means (i) a registration relating to the sale of securities to employees of the Company or a subsidiary pursuant to a stock option, stock purchase, or similar plan; (ii) a registration
relating to an SEC Rule 145 transaction; (iii) a registration on any form that does not include substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities;
or (iv) a registration in which the only Common Stock being registered is Common Stock issuable upon conversion of debt securities that are also being registered. 

1.7 “Form S-1” means such form under the Securities Act
as in effect on the date hereof or any successor registration form under the Securities Act subsequently adopted by the SEC. 
 1.8
“Form S-3” means such form under the Securities Act as in effect on the date hereof or any registration form under the Securities Act subsequently adopted by the SEC that
permits incorporation of substantial information by reference to other documents filed by the Company with the SEC. 
 1.9
“GAAP” means generally accepted accounting principles in the United States. 
 1.10
“Holder” means any holder of Registrable Securities who is a party to this Agreement. 
 1.11
“Immediate Family Member” means a child, stepchild, grandchild, parent, stepparent, grandparent, spouse, sibling, mother-in-law, father-in-law, son-in-law,
daughter-in-law, brother-in-law, or sister-in-law, including, adoptive relationships, of a natural person referred to herein. 

  
 2 

Table of Contents

 1.12 “Initiating Holders” means, collectively, Holders who
properly initiate a registration request under this Agreement. 
 1.13 “IPO” means the Company’s first
underwritten public offering of its Common Stock under the Securities Act. 
 1.14 “Major Investor” means any
Investor that, individually or together with such Investor’s Affiliates, holds at least 187,820 shares of Registrable Securities (as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification
effected after the date hereof); provided that, for purposes of this Agreement, Blackwell Partners LLC—Series A (“Blackwell”) shall be considered a Major Investor; provided further, that any Investor that becomes a
Defaulting Purchaser (as defined in the Purchase Agreement) shall no longer be considered a Major Investor; 
 1.15
“Person” means any individual, corporation, partnership, trust, limited liability company, association or other entity. 

1.16 “Preferred Director” means any director of the Company that the holders of record of the Preferred Stock
are entitled to elect pursuant to the Company’s Certificate of Incorporation. 
 1.17 “Preferred Stock”
means shares of the Company’s Series Seed Preferred Stock and Series B Preferred Stock. 
 1.18 “Registrable
Securities” means (i) the Common Stock issuable or issued upon conversion of the Preferred Stock and (ii) any Common Stock, or any Common Stock issued or issuable (directly or indirectly) upon conversion and/or exercise of any other
securities of the Company, acquired by the Investors after the date hereof; excluding in all cases, however, any Registrable Securities sold by a Person in a transaction in which the applicable rights under this Agreement are not assigned pursuant
to Subsection 5.1, and excluding for purposes of Section 2 any shares for which registration rights have terminated pursuant to Subsection 2.13 of this Agreement. 

1.19 “Registrable Securities then outstanding” means the number of shares determined by adding the number of
shares of outstanding Common Stock that are Registrable Securities and the number of shares of Common Stock issuable (directly or indirectly) pursuant to then exercisable and/or convertible securities that are Registrable Securities. 

1.20 “Restricted Securities” means the securities of the Company required to be notated with the legend set
forth in Subsection 2.12(b) hereof. 
 1.21 “SEC” means the Securities and Exchange Commission. 

1.22 “SEC Rule 144” means Rule 144 promulgated by the SEC under the Securities Act. 

1.23 “SEC Rule 145” means Rule 145 promulgated by the SEC under the Securities Act. 

  
 3 

Table of Contents

 1.24 “Securities Act” means the Securities Act of 1933, as
amended, and the rules and regulations promulgated thereunder. 
 1.25 “Selling Expenses” means all
underwriting discounts, selling commissions, and stock transfer taxes applicable to the sale of Registrable Securities, and fees and disbursements of counsel for any Holder, except for the fees and disbursements of the Selling Holder Counsel borne
and paid by the Company as provided in Subsection 2.6. 
 1.26 “Series B Preferred Stock” means shares
of the Company’s Series B Preferred Stock, par value $0.001 per share. 
 1.27 “Series Seed Preferred
Stock” means shares of the Company’s Series Seed Preferred Stock, par value $0.001 per share. 
 2.
REGISTRATION RIGHTS. The Company covenants and agrees as follows: 

2.1 Demand Registration. 

(a) Form S-1 Demand. If at any time after the earlier of (i) three (3) years after
the date of this Agreement or (ii) one hundred eighty (180) days after the effective date of the registration statement for the IPO, the Company receives a request from Holders of a majority of the Registrable Securities then outstanding
that the Company file a Form S-1 registration statement with respect to a majority of the Registrable Securities then outstanding and if the anticipated aggregate offering price, net of Selling Expenses, would
exceed $10 million, then the Company shall (x) within ten (10) days after the date such request is given, give notice thereof (the “Demand Notice”) to all Holders other than the Initiating Holders; and
(y) as soon as practicable, and in any event within sixty (60) days after the date such request is given by the Initiating Holders, file a Form S-1 registration statement under the Securities Act
covering all Registrable Securities that the Initiating Holders requested to be registered and any additional Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by each such
Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of Subsections 2.1(c) and 2.3. 

(b) Form S-3 Demand. If at any time when it is eligible to use a Form S-3 registration statement, the Company receives a request from Holders of at least thirty percent (30%) of the Registrable Securities then outstanding that the Company file a Form
S-3 registration statement with respect to outstanding Registrable Securities of such Holders having an anticipated aggregate offering price, net of Selling Expenses, of at least $1 million, then the
Company shall (i) within ten (10) days after the date such request is given, give a Demand Notice to all Holders other than the Initiating Holders; and (ii) as soon as practicable, and in any event within forty-five (45) days
after the date such request is given by the Initiating Holders, file a Form S-3 registration statement under the Securities Act covering all Registrable Securities requested to be included in such registration
by any other Holders, as specified by notice given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of Subsections 2.1(c) and 2.3. 

  
 4 

Table of Contents

 (c) Notwithstanding the foregoing obligations, if the Company furnishes to Holders
requesting a registration pursuant to this Subsection 2.1 a certificate signed by the Company’s chief executive officer stating that in the good faith judgment of the Company’s Board of Directors it would be materially
detrimental to the Company and its stockholders for such registration statement to either become effective or remain effective for as long as such registration statement otherwise would be required to remain effective, because such action would
(i) materially interfere with a significant acquisition, corporate reorganization, or other similar transaction involving the Company; (ii) require premature disclosure of material information that the Company has a bona fide business
purpose for preserving as confidential; or (iii) render the Company unable to comply with requirements under the Securities Act or Exchange Act, then the Company shall have the right to defer taking action with respect to such filing for a
period of not more than ninety (90) days after the request of the Initiating Holders is given; provided, however, that the Company may not invoke this right more than once in any twelve (12) month period. 

(d) The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to
Subsection 2.1(a)(i) during the period that is thirty (30) days before the Company’s good faith estimate of the date of filing of, and ending on a date that is one hundred eighty (180) days after the effective date of, a
Company-initiated registration, provided that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; (ii) after the Company has effected two registrations
pursuant to Subsection 2.1(a); or (iii) if the Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately registered on Form S-3 pursuant to a request
made pursuant to Subsection 2.1(b). The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Subsection 2.1(b) (i) during the period that is thirty (30) days before
the Company’s good faith estimate of the date of filing of, and ending on a date that is one hundred eighty (180) after the effective date of, a Company-initiated registration, provided that the Company is actively employing in good
faith commercially reasonable efforts to cause such registration statement to become effective; or (ii) if the Company has effected two registrations pursuant to Subsection 2.1(b) within the twelve (12) month period immediately
preceding the date of such request. A registration shall not be counted as “effected” for purposes of this Subsection 2.1(d) until such time as the applicable registration statement has been declared effective by the SEC,
unless the Initiating Holders withdraw their request for such registration, elect not to pay the registration expenses therefor, and forfeit their right to one demand registration statement pursuant to Subsection 2.6, in which case such
withdrawn registration statement shall be counted as “effected” for purposes of this Subsection 2.1(d). 
 2.2
Company Registration. If the Company proposes to register (including, for this purpose, a registration effected by the Company for stockholders other than the Holders) any of its securities under the Securities Act in connection with the
public offering of such securities solely for cash (other than in an Excluded Registration), the Company shall, at such time, promptly give each Holder notice of such registration. Upon the request of each Holder given within twenty (20) days after
such notice is given by the Company, the Company shall, subject to the provisions of Subsection 2.3, cause to be registered all of the Registrable Securities that each such Holder has requested to be included in such registration. The Company
shall have the right to terminate or withdraw any registration initiated by it under this Subsection 2.2 before the effective date of such registration, whether or not any Holder has elected to include Registrable Securities in such
registration. The expenses (other than Selling Expenses) of such withdrawn registration shall be borne by the Company in accordance with Subsection 2.6. 

  
 5 

Table of Contents

 2.3 Underwriting Requirements. 

(a) If, pursuant to Subsection 2.1, the Initiating Holders intend to distribute the Registrable Securities covered by
their request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to Subsection 2.1, and the Company shall include such information in the Demand Notice. The underwriter(s) will be selected
by the Company and shall be reasonably acceptable to a majority in interest of the Initiating Holders. In such event, the right of any Holder to include such Holder’s Registrable Securities in such registration shall be conditioned upon such
Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their securities through such underwriting shall
(together with the Company as provided in Subsection 2.4(e)) enter into an underwriting agreement in customary form with the underwriter(s) selected for such underwriting. Notwithstanding any other provision of this Subsection 2.3, if
the managing underwriter(s) advise(s) the Initiating Holders in writing that marketing factors require a limitation on the number of shares to be underwritten, then the Initiating Holders shall so advise all Holders of Registrable Securities that
otherwise would be underwritten pursuant hereto, and the number of Registrable Securities that may be included in the underwriting shall be allocated among such Holders of Registrable Securities, including the Initiating Holders, in proportion (as
nearly as practicable) to the number of Registrable Securities owned by each Holder or in such other proportion as shall mutually be agreed to by all such selling Holders; provided, however, that the number of Registrable Securities
held by the Holders to be included in such underwriting shall not be reduced unless all other securities are first entirely excluded from the underwriting. 

(b) In connection with any offering involving an underwriting of shares of the Company’s capital stock pursuant to Subsection
2.2, the Company shall not be required to include any of the Holders’ Registrable Securities in such underwriting unless the Holders accept the terms of the underwriting as agreed upon between the Company and its underwriters, and then only
in such quantity as the underwriters in their sole discretion determine will not jeopardize the success of the offering by the Company. If the total number of securities, including Registrable Securities, requested by stockholders to be included in
such offering exceeds the number of securities to be sold (other than by the Company) that the underwriters in their reasonable discretion determine is compatible with the success of the offering, then the Company shall be required to include in the
offering only that number of such securities, including Registrable Securities, which the underwriters and the Company in their sole discretion determine will not jeopardize the success of the offering. If the underwriters determine that less than
all of the Registrable Securities requested to be registered can be included in such offering, then the Registrable Securities that are included in such offering shall be allocated among the selling Holders in proportion (as nearly as practicable
to) the number of Registrable Securities owned by each selling Holder or in such other proportions as shall mutually be agreed to by all such selling Holders. Notwithstanding the foregoing, in no event shall (i) the number of Registrable
Securities included in the offering be reduced unless all other securities (other than securities to be sold by the Company) are first entirely excluded from the offering, or (ii) the 

  
 6 

Table of Contents

 
number of Registrable Securities included in the offering be reduced below thirty percent (30%) of the total number of securities included in such offering. For purposes of the provision in this
Subsection 2.3(b) concerning apportionment, for any selling Holder that is a partnership, limited liability company, or corporation, the partners, members, retired partners, retired members, stockholders, and Affiliates of such Holder, or the
estates and Immediate Family Members of any such partners, retired partners, members, and retired members and any trusts for the benefit of any of the foregoing Persons, shall be deemed to be a single “selling Holder,” and any pro rata
reduction with respect to such “selling Holder” shall be based upon the aggregate number of Registrable Securities owned by all Persons included in such “selling Holder,” as defined in this sentence. 

(c) For purposes of Subsection 2.1, a registration shall not be counted as “effected” if, as a result of an exercise
of the underwriter’s cutback provisions in Subsection 2.3(a), fewer than fifty percent (50%) of the total number of Registrable Securities that Holders have requested to be included in such registration statement are
actually included. 
 2.4 Obligations of the Company. Whenever required under this Section 2 to effect the registration
of any Registrable Securities, the Company shall, as expeditiously as reasonably possible: 
 (a) prepare and file with the SEC a
registration statement with respect to such Registrable Securities and use its commercially reasonable efforts to cause such registration statement to become effective and, upon the request of the Holders of a majority of the Registrable Securities
registered thereunder, keep such registration statement effective for a period of up to one hundred twenty (120) days or, if earlier, until the distribution contemplated in the registration statement has been completed; provided,
however, that such one hundred twenty (120) day period shall be extended for a period of time equal to the period the Holder refrains, at the request of an underwriter of Common Stock (or other securities) of the Company, from selling
any securities included in such registration; 
 (b) prepare and file with the SEC such amendments and supplements to such
registration statement, and the prospectus used in connection with such registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition of all securities covered by such registration statement; 

(c) furnish to the selling Holders such numbers of copies of a prospectus, including a preliminary prospectus, as required by the
Securities Act, and such other documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable Securities; 

(d) use its commercially reasonable efforts to register and qualify the securities covered by such registration statement under such
other securities or blue-sky laws of such jurisdictions as shall be reasonably requested by the selling Holders; provided that the Company shall not be required to qualify to do business or to file a
general consent to service of process in any such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; 

  
 7 

Table of Contents

 (e) in the event of any underwritten public offering, enter into and perform its
obligations under an underwriting agreement, in usual and customary form, with the underwriter(s) of such offering; 
 (f) use its
commercially reasonable efforts to cause all such Registrable Securities covered by such registration statement to be listed on a national securities exchange or trading system and each securities exchange and trading system (if any) on which
similar securities issued by the Company are then listed; 
 (g) provide a transfer agent and registrar for all Registrable
Securities registered pursuant to this Agreement and provide a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration; 

(h) promptly make available for inspection by the selling Holders, any managing underwriter(s) participating in any disposition
pursuant to such registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling Holders, all financial and other records, pertinent corporate documents, and properties of the
Company, and cause the Company’s officers, directors, employees, and independent accountants to supply all information reasonably requested by any such seller, underwriter, attorney, accountant, or agent, in each case, as necessary or advisable
to verify the accuracy of the information in such registration statement and to conduct appropriate due diligence in connection therewith; 

(i) notify each selling Holder, promptly after the Company receives notice thereof, of the time when such registration statement has
been declared effective or a supplement to any prospectus forming a part of such registration statement has been filed; and 
 (j)
after such registration statement becomes effective, notify each selling Holder of any request by the SEC that the Company amend or supplement such registration statement or prospectus. 

In addition, the Company shall ensure that, at all times after any registration statement covering a public offering of securities of the
Company under the Securities Act shall have become effective, its insider trading policy shall provide that the Company’s directors may implement a trading program under Rule 10b5-1 of the Exchange Act.

 2.5 Furnish Information. It shall be a condition precedent to the obligations of the Company to take any action pursuant to
this Section 2 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself, the Registrable Securities held by it, and the intended method of
disposition of such securities as is reasonably required to effect the registration of such Holder’s Registrable Securities. 
 2.6
Expenses of Registration. All expenses (other than Selling Expenses) incurred in connection with registrations, filings, or qualifications pursuant to Section 2, including all registration, filing, and qualification fees;
printers’ and accounting fees; fees and disbursements of counsel for the Company; and the reasonable fees and disbursements, not to exceed $25,000 per registration, of one counsel for the selling Holders (“Selling Holder
Counsel”), 

  
 8 

Table of Contents

 
shall be borne and paid by the Company; provided, however, that the Company shall not be required to pay for any expenses of any registration proceeding begun pursuant to
Subsection 2.1 if the registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities to be registered (in which case all selling Holders shall bear such expenses pro rata based upon
the number of Registrable Securities that were to be included in the withdrawn registration), unless the Holders of a majority of the Registrable Securities agree to forfeit their right to one registration pursuant to Subsections 2.1(a) or
2.1(b), as the case may be; provided further that if, at the time of such withdrawal, the Holders shall have learned of a material adverse change in the condition, business, or prospects of the Company from that known to the Holders at
the time of their request and have withdrawn the request with reasonable promptness after learning of such information then the Holders shall not be required to pay any of such expenses and shall not forfeit their right to one registration pursuant
to Subsections 2.1(a) or 2.1(b). All Selling Expenses relating to Registrable Securities registered pursuant to this Section 2 shall be borne and paid by the Holders pro rata on the basis of the number of Registrable
Securities registered on their behalf. 
 2.7 Delay of Registration. No Holder shall have any right to obtain or seek an
injunction restraining or otherwise delaying any registration pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 2. 

2.8 Indemnification. If any Registrable Securities are included in a registration statement under this Section 2:

 (a) To the extent permitted by law, the Company will indemnify and hold harmless each selling Holder, and the partners, members,
officers, directors, and stockholders of each such Holder; legal counsel and accountants for each such Holder; any underwriter (as defined in the Securities Act) for each such Holder; and each Person, if any, who controls such Holder or underwriter
within the meaning of the Securities Act or the Exchange Act, against any Damages, and the Company will pay to each such Holder, underwriter, controlling Person, or other aforementioned Person any legal or other expenses reasonably incurred thereby
in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this Subsection 2.8(a) shall not
apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Company, which consent shall not be unreasonably withheld, nor shall the Company be liable for any Damages to the extent
that they arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of any such Holder, underwriter, controlling Person, or other aforementioned Person expressly
for use in connection with such registration. 
 (b) To the extent permitted by law, each selling Holder, severally and not jointly,
will indemnify and hold harmless the Company, and each of its directors, each of its officers who has signed the registration statement, each Person (if any), who controls the Company within the meaning of the Securities Act, legal counsel and
accountants for the Company, any underwriter (as defined in the Securities Act), any other Holder selling securities in such registration statement, and any controlling Person of any such underwriter or other

  
 9 

Table of Contents

 
Holder, against any Damages, in each case only to the extent that such Damages arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information
furnished by or on behalf of such selling Holder expressly for use in connection with such registration; and each such selling Holder will pay to the Company and each other aforementioned Person any legal or other expenses reasonably incurred
thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this Subsection 2.8(b)
shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Holder, which consent shall not be unreasonably withheld; and provided further that in no event
shall the aggregate amounts payable by any Holder by way of indemnity or contribution under Subsections 2.8(b) and 2.8(d) exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder),
except in the case of fraud or willful misconduct by such Holder. 
 (c) Promptly after receipt by an indemnified party under this
Subsection 2.8 of notice of the commencement of any action (including any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect thereof is to be made
against any indemnifying party under this Subsection 2.8, give the indemnifying party notice of the commencement thereof. The indemnifying party shall have the right to participate in such action and, to the extent the indemnifying party so
desires, participate jointly with any other indemnifying party to which notice has been given, and to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party (together
with all other indemnified parties that may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified
party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such action. 

(d) To provide for just and equitable contribution to joint liability under the Securities Act in any case in which either:
(i) any party otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this Subsection 2.8 but it is judicially determined (by the entry of a final judgment or decree by a court of competent
jurisdiction and the expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding the fact that this Subsection 2.8 provides for indemnification in such
case, or (ii) contribution under the Securities Act may be required on the part of any party hereto for which indemnification is provided under this Subsection 2.8, then, and in each such case, such parties will contribute to the
aggregate losses, claims, damages, liabilities, or expenses to which they may be subject (after contribution from others) in such proportion as is appropriate to reflect the relative fault of each of the indemnifying party and the indemnified party
in connection with the statements, omissions, or other actions that resulted in such loss, claim, damage, liability, or expense, as well as to reflect any other relevant equitable considerations. The relative fault of the indemnifying party and of
the indemnified party shall be determined by reference to, among other things, whether the untrue or allegedly untrue statement of a material fact, or the omission or alleged omission of a material fact, relates to information supplied by the
indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information, and opportunity to 

  
 10 

Table of Contents

 
correct or prevent such statement or omission; provided, however, that, in any such case (x) no Holder will be required to contribute any amount in excess of the public
offering price of all such Registrable Securities offered and sold by such Holder pursuant to such registration statement, and (y) no Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act)
will be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation; and provided further that in no event shall a Holder’s liability pursuant to this Subsection 2.8(d), when combined
with the amounts paid or payable by such Holder pursuant to Subsection 2.8(b), exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of willful misconduct or fraud
by such Holder. 
 (e) Unless otherwise superseded by an underwriting agreement entered into in connection with the underwritten
public offering, the obligations of the Company and Holders under this Subsection 2.8 shall survive the completion of any offering of Registrable Securities in a registration under this Section 2, and otherwise shall
survive the termination of this Agreement. 
 2.9 Reports Under Exchange Act. With a view to making available to the Holders
the benefits of SEC Rule 144 and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form
S-3, the Company shall: 
 (a) make and keep available adequate current public information,
as those terms are understood and defined in SEC Rule 144, at all times after the effective date of the registration statement filed by the Company for the IPO; 

(b) use commercially reasonable efforts to file with the SEC in a timely manner all reports and other documents required of the
Company under the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements); and 

(c) furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) to the extent
accurate, a written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any time after ninety (90) days after the effective date of the registration statement filed by the Company for the IPO), the
Securities Act, and the Exchange Act (at any time after the Company has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form S-3
(at any time after the Company so qualifies); (ii) a copy of the most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company; and (iii) such other information as may be reasonably requested
in availing any Holder of any rule or regulation of the SEC that permits the selling of any such securities without registration (at any time after the Company has become subject to the reporting requirements under the Exchange Act) or pursuant to
Form S-3 (at any time after the Company so qualifies to use such form). 

  
 11 

Table of Contents

 2.10 Limitations on Subsequent Registration Rights. From and after the date of this
Agreement, the Company shall not, without the prior written consent of the Holders of a majority of the Registrable Securities then outstanding, enter into any agreement with any holder or prospective holder of any securities of the Company that
would allow such holder or prospective holder (i) to include such securities in any registration unless, under the terms of such agreement, such holder or prospective holder may include such securities in any such registration only to
the extent that the inclusion of such securities will not reduce the number of the Registrable Securities of the Holders that are included; or (ii) to initiate a demand for registration of any securities held by such holder or
prospective holder; provided that this limitation shall not apply to any additional Investor who becomes a party to this Agreement in accordance with Subsection 5.9. 

2.11 “Market Stand-off” Agreement. Each Holder hereby agrees that it will not,
without the prior written consent of the managing underwriter, during the period commencing on the date of the final prospectus relating to the registration by the Company of shares of its Common Stock or any other equity securities under the
Securities Act on a registration statement on Form S-1 or Form S-3, and ending on the date specified by the Company and the managing underwriter (such period not to exceed one hundred eighty (180) days in the case of the IPO, or such
other period as may be requested by the Company or an underwriter to accommodate regulatory restrictions on (1) the publication or other distribution of research reports, and (2) analyst recommendations and opinions,
including, but not limited to, the restrictions contained in FINRA Rule 2711(f)(4) or NYSE Rule 472(f)(4), or any successor provisions or amendments thereto), (i) lend; offer; pledge; sell; contract to sell; sell any option or contract to purchase;
purchase any option or contract to sell; grant any option, right, or warrant to purchase; or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable
(directly or indirectly) for Common Stock, held immediately before the effective date of the registration statement for such offering or (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of
the economic consequences of ownership of such securities, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Common Stock or other securities, in cash, or otherwise. The foregoing
provisions of this Subsection 2.11 shall apply only to the IPO, shall not apply to the sale of any shares to an underwriter pursuant to an underwriting agreement, or the transfer of any shares to any trust for the direct or indirect benefit
of the Holder or the immediate family of the Holder, provided that the trustee of the trust agrees to be bound in writing by the restrictions set forth herein, and provided further that any such transfer shall not involve a
disposition for value, and shall be applicable to the Holders only if all officers, directors and stockholders individually owning more than one percent (1%) of the Company’s outstanding Common Stock are subject to the same restrictions. The
underwriters in connection with such registration are intended third-party beneficiaries of this Subsection 2.11 and shall have the right, power and authority to enforce the provisions hereof as though
they were a party hereto. Each Holder further agrees to execute such agreements as may be reasonably requested by the underwriters in connection with such registration that are consistent with this Subsection 2.11 or that are necessary to
give further effect thereto. The provisions of this Subsection 2.11 shall apply only to the Preferred Stock under this Agreement, and shall not apply to any shares the Company has purchased in the IPO or through the open market. 

  
 12 

Table of Contents

 2.12 Restrictions on Transfer. 

(a) The Preferred Stock and the Registrable Securities shall not be sold, pledged, or otherwise transferred, and the Company shall not
recognize and shall issue stop-transfer instructions to its transfer agent with respect to any such sale, pledge, or transfer, except upon the conditions specified in this Agreement, which conditions are intended to ensure compliance with the
provisions of the Securities Act. A transferring Holder will cause any proposed purchaser, pledgee, or transferee of the Preferred Stock and the Registrable Securities held by such Holder to agree to take and hold such securities subject to the
provisions and upon the conditions specified in this Agreement. 
 (b) Each certificate, instrument, or book entry representing
(i) the Preferred Stock, (ii) the Registrable Securities, and (iii) any other securities issued in respect of the securities referenced in clauses (i) and (ii), upon any stock split, stock dividend, recapitalization, merger,
consolidation, or similar event, shall (unless otherwise permitted by the provisions of Subsection 2.12(c)) be notated with a legend substantially in the following form: 

THE SECURITIES REPRESENTED HEREBY HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933. SUCH SHARES
MAY NOT BE SOLD, PLEDGED, OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR A VALID EXEMPTION FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT. 

THE SECURITIES REPRESENTED HEREBY MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF AN AGREEMENT BETWEEN THE COMPANY AND THE STOCKHOLDER,
A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY. 
 The Holders consent to the Company making a notation in its records and
giving instructions to any transfer agent of the Restricted Securities in order to implement the restrictions on transfer set forth in this Subsection 2.12. 

(c) The holder of such Restricted Securities, by acceptance of ownership thereof, agrees to comply in all respects with the provisions
of this Section 2. Before any proposed sale, pledge, or transfer of any Restricted Securities, unless there is in effect a registration statement under the Securities Act covering the proposed transaction, the Holder
thereof shall give notice to the Company of such Holder’s intention to effect such sale, pledge, or transfer. Each such notice shall describe the manner and circumstances of the proposed sale, pledge, or transfer in sufficient detail and, if
reasonably requested by the Company, shall be accompanied at such Holder’s expense by either (i) a written opinion of legal counsel who shall, and whose legal opinion shall, be reasonably satisfactory to the Company, addressed to the
Company, to the effect that the proposed transaction may be effected without registration under the Securities Act; (ii) a “no action” letter from the SEC to the effect that the proposed sale, pledge, or transfer of such Restricted
Securities without registration will not result in a recommendation by the staff of the SEC that action be taken with respect thereto; or (iii) any other evidence reasonably satisfactory to counsel to the Company to the effect that the proposed
sale, pledge, or transfer of the Restricted Securities may be effected without registration under the Securities Act, whereupon the Holder of such Restricted Securities shall be entitled to sell, 

  
 13 

Table of Contents

 
pledge, or transfer such Restricted Securities in accordance with the terms of the notice given by the Holder to the Company. The Company will not require such a legal opinion or “no
action” letter (x) in any transaction in compliance with SEC Rule 144; or (y) in any transaction in which such Holder distributes Restricted Securities to an Affiliate of such Holder; provided that each transferee agrees in
writing to be subject to the terms of this Subsection 2.12. Each certificate, instrument, or book entry representing the Restricted Securities transferred as above provided shall be notated with, except if such transfer is made pursuant to
SEC Rule 144, the appropriate restrictive legend set forth in Subsection 2.12(b), except that such certificate instrument, or book entry shall not be notated with such restrictive legend if, in the opinion of counsel for such Holder and the
Company, such legend is not required in order to establish compliance with any provisions of the Securities Act. For the avoidance of doubt, a customary arrangement in connection with the deposit of Registrable Securities in a non-margin custodial account shall not be deemed a sale, pledge or transfer for purposes of this Agreement so long as such registrable securities are in certificated form (it being understood that the Company may
require the exchange of any such certificated securities for book-entry shares upon the IPO). 
 2.13 Termination of Registration
Rights. The right of any Holder to request registration or inclusion of Registrable Securities in any registration pursuant to Subsections 2.1 or 2.2 shall terminate upon the earliest to occur of: 

(a) the closing of a Deemed Liquidation Event, as such term is defined in the Company’s Certificate of Incorporation; 

(b) such time as Rule 144 or another similar exemption under the Securities Act is available for the sale of all of such
Holder’s shares without limitation during a three-month period without registration; and 
 (c) the five (5) year
anniversary of the IPO. 
 3. INFORMATION AND OBSERVER
RIGHTS. 
 3.1 Delivery of Financial Statements. The Company shall deliver to each Major Investor: 

(a) as soon as practicable, but in any event within one hundred twenty (120) days after the end of each fiscal year of the Company
(i) a balance sheet as of the end of such year, (ii) statements of income and of cash flows for such year, and (iii) a statement of stockholders’ equity as of the end of such year, all prepared in accordance with GAAP; 

(b) as soon as practicable, but in any event within forty-five (45) days after the end of
each of the first three (3) quarters of each fiscal year of the Company, unaudited statements of income and cash flows for such fiscal quarter, and an unaudited balance sheet as of the end of such fiscal quarter, all prepared in accordance with
GAAP (except that such financial statements may (i) be subject to normal year-end audit adjustments; and (ii) not contain all notes thereto that may be required in accordance with GAAP); 

  
 14 

Table of Contents

 (c) as soon as practicable before the end of each fiscal year, a budget and business plan
for the next fiscal year, approved by the Board of Directors and prepared on a monthly basis, including balance sheets, income statements, and statements of cash flow for such months and, promptly after prepared, any other budgets or revised budgets
prepared by the Company; and 
 (d) such other information relating to the financial condition, business, prospects, or corporate
affairs of the Company as any Major Investor may from time to time reasonably request; provided, however, that the Company shall not be obligated under this Subsection 3.1 to provide information (i) that the Company
reasonably determines in good faith to be a trade secret or confidential information (unless covered by an enforceable confidentiality agreement, in a form acceptable to the Company, including Subsection 3.5 hereof); or (ii) the
disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel. 
 If, for any period, the
Company has any subsidiary whose accounts are consolidated with those of the Company, then in respect of such period the financial statements delivered pursuant to the foregoing sections shall be the consolidated and consolidating financial
statements of the Company and all such consolidated subsidiaries. 
 Notwithstanding anything else in this Subsection 3.1 to the
contrary, the Company may cease providing the information set forth in this Subsection 3.1 during the period starting with the date sixty (60) days before the Company’s good-faith estimate of the date of filing of a registration
statement if it reasonably concludes it must do so to comply with the SEC rules applicable to such registration statement and related offering; provided that the Company’s covenants under this Subsection 3.1 shall be reinstated at
such time as the Company is no longer actively employing its commercially reasonable efforts to cause such registration statement to become effective. 

3.2 Inspection. The Company shall permit each Major Investor, at such Major Investor’s expense, to visit and inspect the
Company’s properties; examine its books of account and records; and discuss the Company’s affairs, finances, and accounts with its officers, during normal business hours of the Company as may be reasonably requested by the Major Investor;
provided, however, that the Company shall not be obligated pursuant to this Subsection 3.2 to provide access to any information that it reasonably and in good faith considers to be a trade secret or confidential information
(unless covered by an enforceable confidentiality agreement, in form acceptable to the Company, including Subsection 3.5 hereof) or the disclosure of which would adversely affect the attorney-client privilege between the Company and its
counsel. 
 3.3 Observer Rights. As long as RA Capital Healthcare Fund, L.P. (“RA Capital”) and its
Affiliates continue to own beneficially at least fifty percent (50%) of the shares of Series B Preferred Stock that RA Capital purchases at the Initial Closing (as defined in the Purchase Agreement) (or an equivalent amount of Common Stock issued
upon conversion thereof), which number is subject to appropriate adjustment for all stock splits, dividends, combinations, recapitalizations and the like, the Company shall invite a representative of RA Capital to attend all meetings of its Board of
Directors in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its directors at the same time and in the same manner as provided to

  
 15 

Table of Contents

 
such directors; provided, however, that such representative shall agree to hold in confidence and trust and to act in a fiduciary manner with respect to all information so provided; and provided
further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting could adversely affect the attorney-client
privilege between the Company and its counsel or result in disclosure of trade secrets or a conflict of interest, or if such Investor or its representative is a competitor of the Company. Notwithstanding the foregoing, if RA Capital becomes a
Defaulting Purchaser (as defined in the Purchase Agreement), it shall no longer have the right under this Section 3.3 to appoint an observer to the Board or to receive the information contemplated under this Section 3.3. 

3.4 Termination of Information and Observer Rights. The covenants set forth in Subsection 3.1, Subsection 3.2 and
Subsection 3.3 shall terminate and be of no further force or effect (i) immediately before the consummation of the IPO, or (ii) when the Company first becomes subject to the periodic reporting requirements of
Section 12(g) or 15(d) of the Exchange Act, or (iii) upon a Deemed Liquidation Event, as such term is defined in the Company’s Certificate of Incorporation, whichever event occurs first. 

3.5 Confidentiality. Each Investor agrees that such Investor will keep confidential and will not disclose, divulge, or use for
any purpose (other than to monitor its investment in the Company) any confidential information obtained from the Company pursuant to the terms of this Agreement (including notice of the Company’s intention to file a registration statement),
unless such confidential information (a) is known or becomes known to the public in general (other than as a result of a breach of this Subsection 3.5 by such Investor), (b) is or has been independently developed or conceived by
the Investor without use of the Company’s confidential information, or (c) is or has been made known or disclosed to the Investor by a third party without a breach of any obligation of confidentiality such third party may have to
the Company; provided, however, that an Investor may disclose confidential information (i) to its attorneys, accountants, consultants, advisors and other professionals to the extent necessary to obtain their services in
connection with monitoring its investment in the Company; (ii) to any prospective purchaser of any Registrable Securities from such Investor, if such prospective purchaser agrees to be bound by the provisions of this Subsection
3.5; (iii) to any Affiliate, partner, member, stockholder, current or prospective investor or wholly owned subsidiary of such Investor in the ordinary course of business, provided that such Investor informs such Person that such
information is confidential and directs such Person to maintain the confidentiality of such information; or (iv) as may otherwise be required by law, provided that the Investor promptly notifies the Company of such disclosure and
takes reasonable steps to minimize the extent of any such required disclosure. 
 3.6 Press Releases. The Company agrees not
to (a) issue any press release that uses the name of Investor or its Affiliates or (b) make any other statement communication to any third party (other than to its legal, accounting and financial advisors, and other than to
potential investors or acquirers under a duty of confidentiality) that uses the name of Investor or its Affiliates name without first allowing Investor to review and comment on such press release, statement or communication. 

  
 16 

Table of Contents

 3.7 Auditor Independence. The Company shall be reasonably responsive to requests
for information from the Investor relating to issues that may impact auditor independence rules applicable to the Investor. 
 4.
ADDITIONAL COVENANTS. 
 4.1 Insurance. The Company shall use its commercially
reasonable efforts to obtain, within ninety (90) days of the date hereof, from financially sound and reputable insurers Directors and Officers liability insurance, each in an amount and on terms and conditions satisfactory to the Board
of Directors, and will use commercially reasonable efforts to cause such insurance policies to be maintained until such time as the Board of Directors determines that such insurance should be discontinued. Notwithstanding any other provision of this
Section 4.1 to the contrary, for so long as a Preferred Director (as defined in the Company’s Certificate of Incorporation) is serving on the Board of Directors, the Company shall not cease to maintain a Directors and Officers
liability insurance policy in an amount of at least $2 million unless approved by at least one Preferred Director. 
 4.2
Employee Agreements. The Company will cause each person now or hereafter employed by it or by any subsidiary (or engaged by the Company or any subsidiary as a consultant/independent contractor) with access to confidential information and/or
trade secrets to enter into a nondisclosure and proprietary rights assignment agreement. 
 4.3 Employee Stock. Unless
otherwise approved by the Board of Directors, including at least one Preferred Director, all future employees and consultants of the Company who purchase, receive options to purchase, or receive awards of shares of the Company’s capital stock
after the date hereof shall be required to execute restricted stock or option agreements, as applicable, providing for (i) vesting of shares over a four (4) year period, with the first twenty-five percent (25%) of such shares
vesting following twelve (12) months of continued employment or service, and the remaining shares vesting in equal monthly installments over the following thirty-six (36) months, and (ii) a market stand-off
provision substantially similar to that in Subsection 2.11. In addition, unless otherwise approved by the Board of Directors, the Company shall retain a “right of first refusal” on employee transfers until the Company’s IPO and
shall have the right to repurchase unvested shares at cost upon termination of employment of a holder of restricted stock. 
 4.4
Board and Observer Matters. The Company shall reimburse its directors and board observers for all reasonable out-of-pocket travel expenses incurred in connection with attending meetings of the Board of Directors. 

4.5 Successor Indemnification. If the Company or any of its successors or assignees consolidates with or merges into any other
Person and is not the continuing or surviving corporation or entity of such consolidation or merger, then to the extent necessary, proper provision shall be made so that the successors and assignees of the Company assume the obligations of the
Company with respect to indemnification of members of the Board of Directors as in effect immediately before such transaction, whether such obligations are contained in the Company’s Bylaws, its Certificate of Incorporation, or elsewhere, as
the case may be. 

  
 17 

Table of Contents

 4.6 Indemnification Matters. The Company hereby acknowledges that one
(1) or more of the directors nominated to serve on the Board of Directors by the Investors (each a “Fund Director”) may have certain rights to indemnification, advancement of expenses and/or insurance provided by one or
more of the Investors and certain of their affiliates (collectively, the “Fund Indemnitors”). The Company hereby agrees (a) that it is the indemnitor of first resort (i.e., its obligations to any such
Fund Director are primary and any obligation of the Fund Indemnitors to advance expenses or to provide indemnification for the same expenses or liabilities incurred by such Fund Director are secondary), (b) that it shall be required to advance the
full amount of expenses incurred by such Fund Director and shall be liable for the full amount of all expenses, judgments, penalties, fines and amounts paid in settlement by or on behalf of any such Fund Director to the extent legally permitted and
as required by the Company’s Certificate of Incorporation or Bylaws of the Company (or any agreement between the Company and such Fund Director), without regard to any rights such Fund Director may have against the Fund Indemnitors, and,
(c) that it irrevocably waives, relinquishes and releases the Fund Indemnitors from any and all claims against the Fund Indemnitors for contribution, subrogation or any other recovery of any kind in respect thereof. The
Company further agrees that no advancement or payment by the Fund Indemnitors on behalf of any such Fund Director with respect to any claim for which such Fund Director has sought indemnification from the Company shall affect the foregoing and the
Fund Indemnitors shall have a right of contribution and/or be subrogated to the extent of such advancement or payment to all of the rights of recovery of such Fund Director against the Company. 

4.7 Right to Conduct Activities. The Company hereby agrees and acknowledges that BridgeBio Pharma LLC (together with its
Affiliates) (“BridgeBio”), RA Capital (together with its Affiliates), Viking Global Opportunities Illiquid Investments Sub-Master LP (together with its Affiliates, “Viking”), Amzak Health Investors, LLC (together
with its Affiliates, “Amzak”), Aisling Capital IV, LP (together with its Affiliates, “Aisling”) and Blackwell (together with its Affiliates) are each professional investment funds, and as such invest in numerous
portfolio companies, some of which may be deemed competitive with the Company’s business (as currently conducted or as currently proposed to be conducted). The Company hereby agrees that, to the extent permitted under applicable law, each of
BridgeBio, RA Capital (together with its Affiliates), Viking, Amzak, Aisling and Blackwell (together with its Affiliates) shall not be liable to the Company for any claim arising out of, or based upon, (i) the investment by any of
BridgeBio, RA Capital or its Affiliates, Viking, Amzak, Aisling or Blackwell or its Affiliates in any entity competitive with the Company, or (ii) actions taken by any partner, officer or other representative of any of BridgeBio, RA
Capital or its Affiliates, Viking, Amzak, Aisling or Blackwell or its Affiliates to assist any such competitive company, whether or not such action was taken as a member of the board of directors of such competitive company or otherwise, and whether
or not such action has a detrimental effect on the Company; provided, however, that the foregoing shall not relieve (x) any of the Investors from liability associated with the unauthorized disclosure of the Company’s confidential
information obtained pursuant to this Agreement, or (y) any director or officer of the Company from any liability associated with his or her fiduciary duties to the Company. 

  
 18 

Table of Contents

 4.8 Public Company Information. The Company understands and acknowledges that, in
the regular course of Viking’s and Amzak’s businesses, each of them and their Affiliates may invest in companies that have issued securities that are publicly traded (each, a “Public Company”). Accordingly, the Company
covenants and agrees that before providing material non-public information about a Public Company (“Public Company Information”) to Viking and/or Amzak, the Company will provide prior written notice describing the nature of such
information in reasonable detail. The Company shall not disclose Public Company Information to Viking, Amzak or their respective Affiliates without prior written authorization from Viking’s or Amzak’s respective legal and compliance
personnel. 
 4.9 FCPA. The Company represents that it shall not (and shall not permit any of its subsidiaries or affiliates
or any of its or their respective directors, officers, managers, employees, independent contractors, representatives or agents to) promise, authorize or make any payment to, or otherwise contribute any item of value to, directly or indirectly, to
any third party, including any Non-U.S. Official (as (as such term is defined in the U.S. Foreign Corrupt Practices Act of 1977, as amended (the “FCPA”)), in each case, in violation of the FCPA, the U.K. Bribery Act, or any other
applicable anti-bribery or anti-corruption law. The Company further represents that it shall (and shall cause each of its subsidiaries and affiliates to) cease all of its or their respective activities, as well as remediate any actions taken by the
Company, its subsidiaries or affiliates, or any of their respective directors, officers, managers, employees, independent contractors, representatives or agents in violation of the FCPA, the U.K. Bribery Act, or any other applicable anti-bribery or
anti-corruption law. The Company further represents that it shall (and shall cause each of its subsidiaries and affiliates to) maintain systems of internal controls (including, but not limited to, accounting systems, purchasing systems
and billing systems) to ensure compliance with the FCPA, the U.K. Bribery Act, or any other applicable anti-bribery or anti-corruption law. Upon request, the Company agrees to provide responsive information and/or certifications
concerning its compliance with applicable anti-corruption laws. The Company shall promptly notify each Investor if the Company becomes aware of any Enforcement Action (as defined in the Purchase Agreement). The Company shall,
and shall cause any direct or indirect subsidiary or entity controlled by it, whether now in existence or formed in the future, to comply with the FCPA. The Company shall use its best efforts to cause any direct or indirect subsidiary,
whether now in existence or formed in the future, to comply in all material respects with all applicable laws. 
 4.10 Termination
of Covenants. The covenants set forth in this Section 4, except for Subsections 4.5, 4.7 and 4.8 shall terminate and be of no further force or effect (i) immediately before the consummation of the IPO
or (ii) when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act, or (iii) upon a Deemed Liquidation Event, as such term is defined in the
Company’s Certificate of Incorporation, whichever event occurs first. 

  
 19 

Table of Contents

 5. RIGHTS OF FIRST REFUSAL.

 5.1 Subsequent Offerings. Subject to applicable securities laws, each Investor shall have a right of first refusal to
purchase its pro rata share of all Equity Securities, as defined below, that the Company may, from time to time, propose to sell and issue after the date of this Agreement, other than the Equity Securities excluded by Section 5.7
hereof. Each Investor’s pro rata share is equal to the ratio of (a) the number of shares of the Company’s Common Stock (including all shares of Common Stock issuable or issued upon conversion of the shares or upon the
exercise of outstanding warrants or options) of which such Investor is deemed to be a holder immediately prior to the issuance of such Equity Securities to (b) the total number of shares of the Company’s outstanding Common Stock
(including all shares of Common Stock issued or issuable upon conversion of the shares or upon the exercise of any outstanding warrants or options) immediately prior to the issuance of the Equity Securities. The term “Equity
Securities” shall mean (i) any Common Stock, Preferred Stock or other equity security of the Company, (ii) any security convertible into or exercisable or exchangeable for, with or without consideration, any Common
Stock, Preferred Stock or other equity security (including any option to purchase such a convertible security), (iii) any equity security carrying any warrant or right to subscribe to or purchase any Common Stock, Preferred Stock or
other security or (iv) any such warrant or right. 
 5.2 Exercise of Rights. If the Company proposes to issue any Equity
Securities, it shall give each Investor written notice of its intention, describing the Equity Securities, the price and the terms and conditions upon which the Company proposes to issue the same. Each Investor shall have fifteen
(15) days from the giving of such notice to agree to purchase up to that portion of such Equity Securities that equals the proportion that the number of shares of Registrable Securities issued and held by such Investor (assuming full
conversion, exercise and/or exchange of all convertible, exercisable and/or exchangeable securities then outstanding) bears to the total number of shares of Common Stock of the Company then outstanding (assuming full conversion, exercise and/or
exchange of all convertible, exercisable and/or exchangeable securities then outstanding) for the price and upon the terms and conditions specified in the notice by giving written notice to the Company and stating therein the quantity of Equity
Securities to be purchased. Notwithstanding the foregoing, the Company shall not be required to offer or sell such Equity Securities to any Investor who would cause the Company to be in violation of applicable federal securities laws by virtue of
such offer or sale. 
 5.3 Issuance of Equity Securities to Other Persons. If not all of the Investors elect to purchase all the
Equity Securities available to them pursuant to Section 5.2, then the Company shall promptly notify in writing the Investors who do so elect to purchase all the Equity Securities available to them pursuant to Section 5.2 (a
“Fully-Exercising Investor”) and shall offer such Fully-Exercising Investors the right to acquire such number of unsubscribed shares that is equal to the proportion that the number of shares of Registrable Securities issued and held
by such Fully-Exercising Investor bears to the total number of shares of Common Stock issued and held, or issuable upon conversion of the Preferred Stock then held, by all Fully-Exercising Investors who wish to purchase some of the unsubscribed
shares. The Fully-Exercising Investors shall have five (5) days after receipt of such notice to notify the Company of its election to purchase all or a portion thereof of the unsubscribed shares. The Company shall have ninety
(90) days thereafter to sell the Equity Securities in respect of which the Investor’s rights were not exercised, at a price and upon general terms and conditions not materially more favorable to the purchasers thereof than specified
in the Company’s notice to the Investors pursuant to Section 5.2 hereof. If the Company has not sold such Equity Securities within ninety (90) days of the notice provided pursuant to Section 5.2, the Company
shall not thereafter issue or sell any Equity Securities, without first offering such securities to the Investors in the manner provided above. 

  
 20 

Table of Contents

 5.4 Sale Without Notice. In lieu of giving notice to the Investors prior to the
issuance of Equity Securities as provided in Section 5.2, the Company may elect to give notice to the Investors within thirty (30) days after the issuance of Equity Securities. Such notice shall describe the type, price and
terms of the Equity Securities. Each Investor shall have twenty (20) days from the date of receipt of such notice to elect to purchase up to the number of shares that would, if purchased by such Investor, maintain such Investor’s
pro rata share (as set forth in Section 5.1) of the Company’s equity securities after giving effect to all such purchases. The closing of such sale shall occur within sixty (60) days of the date of notice to the
Investors. 
 5.5 Termination and Waiver of Rights of First Refusal. The rights of first refusal established by this
Section 5 shall not apply to, and shall terminate upon the earlier of (i) the effective date of the registration statement pertaining to the IPO or (ii) the closing of a Deemed Liquidation Event (as defined in the
Company’s Certificate of Incorporation). Notwithstanding Section 6.6 hereof, the rights of first refusal established by this Section 5 may be amended, or any provision waived with and only with the written
consent of the Company and the Investors holding a majority of the Registrable Securities held by all Investors, or as permitted by Section 6.6. 

5.6 Assignment of Rights of First Refusal. The rights of first refusal of each Major Investor under this Section 5
may be assigned to the same parties, subject to the same restrictions as any transfer of registration rights pursuant to Section 2.12. 

5.7 Excluded Securities. The rights of first refusal established by this Section 5 shall have no application to any
Equity Securities that are Exempted Securities (as defined in the Company’s Certificate of Incorporation) or any Equity Securities issued by the Company pursuant to the terms of Section 1.3 of the Purchase Agreement. 

6. MISCELLANEOUS. 

6.1 Successors and Assigns. The rights under this Agreement may be assigned (but only with all related obligations) by a Holder
to a transferee of Registrable Securities that (i) is an Affiliate of a Holder; (ii) is a Holder’s Immediate Family Member or trust for the benefit of an individual Holder or one or more of such Holder’s Immediate
Family Members; or (iii) after such transfer, holds at least 100,000 shares of Registrable Securities (subject to appropriate adjustment for stock splits, stock dividends, combinations, and other recapitalizations); provided,
however, that (x) the Company is, within a reasonable time after such transfer, furnished with written notice of the name and address of such transferee and the Registrable Securities with respect to which such rights are being
transferred; and (y) such transferee agrees in a written instrument delivered to the Company to be bound by and subject to the terms and conditions of this Agreement, including the provisions of Subsection 2.11. For the purposes
of determining the number of shares of Registrable Securities held by a transferee, the holdings of a transferee (1) that is an Affiliate or stockholder of a Holder; (2) who is a Holder’s Immediate Family Member; or
(3) that is a trust for the benefit of an individual Holder or such Holder’s Immediate Family Member shall be aggregated together and with those of the 

  
 21 

Table of Contents

 
transferring Holder; provided further that all transferees who would not qualify individually for assignment of rights shall have a single attorney-in-fact for the purpose of
exercising any rights, receiving notices, or taking any action under this Agreement. The terms and conditions of this Agreement inure to the benefit of and are binding upon the respective successors and permitted assignees of the parties. Nothing in
this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and permitted assignees any rights, remedies, obligations or liabilities under or by reason of this Agreement,
except as expressly provided herein. 
 6.2 Governing Law. This Agreement shall be governed by the internal law of the State
of Delaware. 
 6.3 Counterparts. This Agreement may be executed in two (2) or more counterparts, each of which
shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of
2000, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. 

6.4 Titles and Subtitles. The titles and subtitles used in this Agreement are for convenience only and are not to be considered
in construing or interpreting this Agreement. 
 6.5 Notices. All notices and other communications given or made pursuant to
this Agreement shall be in writing and shall be deemed effectively given upon the earlier of actual receipt or (i) personal delivery to the party to be notified; (ii) when sent, if sent by electronic mail or facsimile during
the recipient’s normal business hours, and if not sent during normal business hours, then on the recipient’s next business day; (iii) five (5) days after having been sent by registered or certified mail, return receipt
requested, postage prepaid; or (iv) one (1) business day after the business day of deposit with a nationally recognized overnight courier, freight prepaid, specifying next-day delivery, with written verification of receipt. All
communications shall be sent to the respective parties at their addresses as set forth on Schedule A hereto, or to the principal office of the Company and to the attention of the Chief Executive Officer, in the case of the
Company, or to such email address, facsimile number, or address as subsequently modified by written notice given in accordance with this Subsection 6.5. If notice is given to the Company, a copy shall also be sent to Goodwin Procter, LLP,
Three Embarcadero Center, 28th Floor, San Francisco, CA 94111, Attn: Maggie Wong. 

6.6 Amendments and Waivers. Any term of this Agreement may be amended and the observance of any term of this Agreement may be
waived (either generally or in a particular instance, and either retroactively or prospectively) only with the written consent of the Company and the holders of a majority of the Registrable Securities then outstanding; provided that the
Company may in its sole discretion waive compliance with Subsection 2.12(c) (and the Company’s failure to object promptly in writing after notification of a proposed assignment allegedly in violation of Subsection 2.12(c) shall be
deemed to be a waiver); provided further, that Subsection 1.19 of this Agreement shall not be amended to exclude Blackwell without the written consent of Blackwell; provided further, that Subsections 3.3 and
4.4 shall not be amended or waived without the written consent of RA Capital so long as (x) RA 

  
 22 

Table of Contents

 
Capital and its Affiliates continue to own beneficially at least fifty percent (50%) of the shares of Series B Preferred Stock that RA Capital purchases at the Initial Closing (or an equivalent
amount of Common Stock issued upon conversion thereof) and (y) RA Capital has not become a Defaulting Purchaser (as defined in the Purchase Agreement); provided further, that Subsection 4.7 shall not be amended or waived
without the written consent of BridgeBio, RA Capital, Viking, Amzak, Aisling and Blackwell; and provided further that any provision hereof may be waived by any waiving party on such party’s own behalf, without the consent of any
other party. Notwithstanding the foregoing, (a) this Agreement may not be amended or terminated and the observance of any term hereof may not be waived with respect to any Investor without the written consent of such Investor, unless
such amendment, termination, or waiver applies to all Investors in the same fashion and (b) in the event the rights under Section 5 are waived with respect to an offering of Equity Securities without an Investor’s prior
written consent and any party that participated in waiving such rights actually purchases Equity Securities in such offering, the Company shall grant to any such non-waiving Investor the right to purchase, in a subsequent closing of such issuance on
substantially the same terms and conditions, the same percentage of its full pro rata share of such Equity Securities as the highest percentage of any such purchasing waiving party. The Company shall give prompt notice of any amendment or
termination hereof or waiver hereunder to any party hereto that did not consent in writing to such amendment, termination, or waiver. Any amendment, termination, or waiver effected in accordance with this Subsection 6.6 shall be binding on
all parties hereto, regardless of whether any such party has consented thereto. No waivers of or exceptions to any term, condition, or provision of this Agreement, in any one or more instances, shall be deemed to be or construed as a further or
continuing waiver of any such term, condition, or provision. 
 6.7 Severability. In case any one or more of the provisions
contained in this Agreement is for any reason held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provision of this Agreement, and such invalid, illegal, or
unenforceable provision shall be reformed and construed so that it will be valid, legal, and enforceable to the maximum extent permitted by law. 

6.8 Aggregation of Stock. All shares of Registrable Securities held or acquired by Affiliates shall be aggregated together for
the purpose of determining the availability of any rights under this Agreement and such Affiliated persons may apportion such rights as among themselves in any manner they deem appropriate. 

6.9 Additional Investors. Notwithstanding anything to the contrary contained herein, if the Company issues additional shares of
the Company’s Series B Preferred Stock after the date hereof, any purchaser of such shares of Series B Preferred Stock may become a party to this Agreement by executing and delivering an additional counterpart signature page to this Agreement,
and thereafter shall be deemed an “Investor” for all purposes hereunder. No action or consent by the Investors shall be required for such joinder to this Agreement by such additional Investor, so long as such additional Investor has agreed
in writing to be bound by all of the obligations as an “Investor” hereunder. 
 6.10 Entire Agreement. This
Agreement (including any Schedules and Exhibits hereto) constitutes the full and entire understanding and agreement among the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter
hereof existing between the parties is expressly canceled. Upon the effectiveness of this Agreement, the Prior Agreement shall be deemed amended and restated and superseded and replaced in its entirety by this Agreement, and shall be of no further
force or effect. 

  
 23 

Table of Contents

 6.11 Dispute Resolution. Any unresolved controversy or claim arising out of or
relating to this Agreement, except as (i) otherwise provided in this Agreement, or (ii) any such controversies or claims arising out of either party’s intellectual property rights for which a provisional remedy or
equitable relief is sought, shall be submitted to arbitration by one arbitrator mutually agreed upon by the parties, and if no agreement can be reached within thirty (30) days after names of potential arbitrators have been proposed by
the American Arbitration Association (the “AAA”), then by one arbitrator having reasonable experience in corporate finance transactions of the type provided for in this Agreement and who is chosen by the AAA. The arbitration
shall take place in Palo Alto, California, in accordance with the AAA rules then in effect, and judgment upon any award rendered in such arbitration will be binding and may be entered in any court having jurisdiction thereof. There shall be limited
discovery prior to the arbitration hearing as follows: (a) exchange of witness lists and copies of documentary evidence and documents relating to or arising out of the issues to be arbitrated, (b) depositions of all party
witnesses and (c) such other depositions as may be allowed by the arbitrators upon a showing of good cause. Depositions shall be conducted in accordance with the California Code of Civil Procedure, the arbitrator shall be required to
provide in writing to the parties the basis for the award or order of such arbitrator, and a court reporter shall record all hearings, with such record constituting the official transcript of such proceedings. 

6.12 Delays or Omissions. No delay or omission to exercise any right, power, or remedy accruing to any party under this
Agreement, upon any breach or default of any other party under this Agreement, shall impair any such right, power, or remedy of such nonbreaching or nondefaulting party, nor shall it be construed to be a waiver of or acquiescence to any such breach
or default, or to any similar breach or default thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring. All remedies, whether under this
Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative. 

  
 24 

Table of Contents

 IN WITNESS WHEREOF, the
parties have executed this AGREEMENT as of the date first written above. 
  

			
	EIDOS THERAPEUTICS, INC.
		
	By:	 	/s/ Neil Kumar

 
			
	Name:	 	Neil Kumar

 
			
	Title:	 	Chief Executive Officer

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

Table of Contents

 IN WITNESS WHEREOF, the
parties have executed this AGREEMENT as of the date first written above. 
  

			
	KEY HOLDERS:
		
	Signature:	 	/s/ Isabella Graef

 
			
	Name:	 	Isabella Graef

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

Table of Contents

 IN WITNESS WHEREOF, the
parties have executed this AGREEMENT as of the date first written above. 
  

			
	KEY HOLDERS:
		
	Signature:	 	/s/ Mamoun Alhamadsheh

 
			
	Name:	 	Mamoun Alhamadsheh

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

Table of Contents

 IN WITNESS WHEREOF, the
parties have executed this AGREEMENT as of the date first written above. 
  

			
	KEY HOLDERS:
		
	Signature:	 	/s/ Christine Siu

 
			
	Name:	 	Christine Siu

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

Table of Contents

 IN WITNESS WHEREOF, the
parties have executed this AGREEMENT as of the date first written above. 
  

			
	KEY HOLDERS:
		
	Signature:	 	/s/ Uma Sinha

 
			
	Name:	 	Uma Sinha

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

Table of Contents

 IN WITNESS WHEREOF, the
parties have executed this AGREEMENT as of the date first written above. 
  

			
	KEY HOLDERS:
	
	 Jonathan C Fox and Suzanne Markel-Fox,
Co-Trustees of the Fox Family Trust Dated
 17 Dec 2014

		
	Signature:	 	/s/ Jonathan C Fox

 
			
	Name:	 	Jonathan C Fox

 
			
	Title:	 	Trustee, Fox Family Trust

  

			
		
	Signature:	 	/s/ Suzanne Markel-Fox

 
			
	Name:	 	Suzanne Markel-Fox

 
			
	Title:	 	Trustee, Fox Family Trust

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

Table of Contents

 IN WITNESS WHEREOF, the
parties have executed this AGREEMENT as of the date first written above. 
  

			
	INVESTORS:
	
	BRIDGEBIO PHARMA LLC
		
	By:	 	/s/ Neil Kumar

 
			
	Name:	 	Neil Kumar

 
			
	Title:	 	Chief Executive Officer

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

Table of Contents

 IN WITNESS WHEREOF, the
parties have executed this AGREEMENT as of the date first written above. 
  

			
	INVESTORS:
	
	    RA CAPITAL HEALTHCARE FUND, L.P.
		
	        By:	 	RA Capital Management, LLC

 
			
	        Its:	 	General Partner

  

			
	        By:	 	/s/ Rajeev Shah

 
			
	        Name:	 	Rajeev Shah

 
			
	        Title:	 	Authorized Signatory

 
			
		
	        Address:	 	RA Capital Management, LLC
		 	20 Park Plaza
		 	Suite 1200
		 	Boston, MA 02116
		 	Attn: Rajeev Shah

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

Table of Contents

 IN WITNESS WHEREOF, the
parties have executed this AGREEMENT as of the date first written above. 
  

			
	        INVESTORS:
	
	BLACKWELL PARTNERS LLC – SERIES A
		
	By:	 	/s/ Abayomi A. Adigun

 
			
	Name:	 	Abayomi A. Adigun
	Title:	 	Investment Manager
		 	DUMAC, Inc.
		 	Authorized Signatory

  

			
	By:	 	/s/ Jannine M. Lall

 
			
	Name:	 	Jannine M. Lall
	Title:	 	Controller
		 	DUMAC, Inc.
		 	Authorized Signatory

  

			
	Address:	 	Blackwell Partners LLC – Series A

 
			
		 	280 S. Mangum Street
		 	Suite 210
		 	Durham, NC 27701
		 	Attn: Jannine Lall

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

Table of Contents

 IN WITNESS WHEREOF, the
parties have executed this AGREEMENT as of the date first written above. 
  

			
	        INVESTORS:
	
	AISLING CAPITAL IV, LP
		
	By:	 	/s/ Robert Wenzel

 
			
	Name:	 	Robert Wenzel
	Title:	 	CFO
	
	Aisling Capital IV, L.P.
	888 Seventh Avenue, 12th Floor
	New York, NY 10106
	 Attn: Drew Schiff
 Fax: 212 651
6379

	
	and
	
	Aisling Capital IV, L.P.
	888 Seventh Avenue, 12th Floor
	New York, NY 10106
	Attn: Chief Financial Officer
	Fax: 212 651 6379
	
	With a required copy to:
	
	McDermott Will & Emery LLP
	340 Madison Avenue
	New York, NY 10173-1922
	Attn: Todd Finger
	Fax: 212 547 5444

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

Table of Contents

 IN WITNESS WHEREOF, the
parties have executed this AGREEMENT as of the date first written above. 
  

			
	  INVESTORS:
	
	VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP
		
	    By:	 	Viking Global Opportunities Portfolio
	    GP LLC, its general partner

  

			
		
	    By:	 	/s/ Matthew Bloom

 
			
	    Name:	 	Matthew Bloom
	    Title:	 	Authorized Signatory

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

Table of Contents

 IN WITNESS WHEREOF, the
parties have executed this AGREEMENT as of the date first written above. 
  

			
	    INVESTORS:
	
	AMZAK HEALTH INVESTORS, LLC
		
	    By:	 	/s/ Anders Hove

 
			
	    Name:	 	Anders Hove
	    Title:	 	Manager

  

			
	    Address:	 	980 North Federal Highway
		 	Suite 315
		 	Boca Raton
		 	FL 33432
		 	Attn: Anders Hove

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

Table of Contents

 IN WITNESS WHEREOF, the
parties have executed this AGREEMENT as of the date first written above. 
  

					
	INVESTORS:
		
		 	The Board of Trustees of Leland Stanford Junior University
		
		 	 /s/ Sabrina Liang

		 	Name:	 	Sabrina Liang
		 	Title:	 	 Director, School and Department

Funds

  

			
	        Address:	 	Stanford management Company
		 	635 Knight Way
		 	Stanford, CA 94305-7297

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

Table of Contents

 IN WITNESS WHEREOF, the
parties have executed this AGREEMENT as of the date first written above. 
  

			
	    INVESTORS:
	
	CORMORANT PRIVATE HEALTHCARE FUND I, LP
		
	    By:	 	Cormorant Private Healthcare GP, LLC
		
	    By:	 	/s/ Bihua Chen
		 	Bihua Chen, Managing Member of the GP

 
			
		
	    Address:	 	200 Clarendon Street
		 	52nd Floor
		 	Boston, MA 02116

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

Table of Contents

 IN WITNESS WHEREOF, the
parties have executed this AGREEMENT as of the date first written above. 
  

			
	    INVESTORS:
	
	CORMORANT GLOBAL HEALTHCARE MASTER FUND, LP
		
	        By:	 	Cormorant Private Healthcare GP, LLC
		
	        By:	 	/s/ Bihua Chen
		 	Bihua Chen, Managing Member of the GP

 
			
		
	    Address:	 	200 Clarendon Street
		 	52nd Floor
		 	Boston, MA 02116

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

Table of Contents

 IN WITNESS WHEREOF, the
parties have executed this AGREEMENT as of the date first written above. 
  

			
	    INVESTORS:
	
	CRMA SPV, L.P.
		
	        By:	 	Cormorant Asset Management, LLC
		
	        By:	 	/s/ Bihua Chen

 
			
	        Name:	 	Bihua Chen, CEO/CIO

 
			
	        Its:	 	Attorney-in-Fact

 
			
		
	        Address:	 	PO Box 309
		 	Ugland House
		 	Grand Cayman KY1-1104
		 	Cayman Islands

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

Table of Contents

 IN WITNESS WHEREOF, the
parties have executed this AGREEMENT as of the date first written above. 
  

			
	    INVESTORS:
	
	PERCEPTIVE LIFE SCIENCES MASTER FUND LTD.
		
	        By:	 	/s/ James H Mannix

 
			
	        Name:	 	James H Mannix

 
			
	        Title:	 	COO

 
			
		
	        Address:	 	51 Astor place 10th Floor
		 	New York NY. 10003

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

Table of Contents

 IN WITNESS WHEREOF, the
parties have executed this AGREEMENT as of the date first written above. 
  

			
	INVESTORS:

 
			
	
	JANUS HENDERSON GLOBAL LIFE SCIENCES FUND
	
	     JANUS CAPITAL MANAGEMENT, LLC

    as investment advisor for Janus Henderson

    Global Life Sciences Fund

 
			
		
	    By:	 	/s/ Enrique Chang

 
			
	    Name:	 	Enrique Chang

 
			
	    Title:	 	Authorized Signatory

 
			
		
	    Address:	 	c/o Janus Capital Management, LLC
		 	151 Detroit Street
		 	Denver CO 80206
		 	Attn: Legal Department, 4th Floor

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

Table of Contents

 IN WITNESS WHEREOF, the
parties have executed this AGREEMENT as of the date first written above. 
  

			
	INVESTORS:
	
	JANUS HENDERSON CAPITAL FUNDS PLC ON BEHALF OF ITS SERIES JANUS HENDERSON GLOBAL LIFE SCIENCES FUND
	
	     JANUS CAPITAL MANAGEMENT, LLC

    as investment advisor for Janus Henderson

    Capital Funds PLC on behalf of its series

    Janus Henderson Global Life Sciences 
Fund

 
			
		
	    By:	 	/s/ Enrique Chang

 
			
	    Name:	 	Enrique Chang

 
			
	    Title:	 	Authorized Signatory

 
			
		
	    Address:	 	c/o Janus Capital Management, LLC
		 	151 Detroit Street
		 	Denver CO 80206
		 	Attn: Legal Department, 4th Floor

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

Table of Contents

 SCHEDULE A 

INVESTORS 

BRIDGEBIO PHARMA LLC 

Address: 421 Kipling Street, Palo Alto, CA 94301 
 Phone Number

 Fax Number 
 Email: nk@bridgebio.com 

THE BOARD OF TRUSTEES OF LELAND STANFORD
JUNIOR UNIVERSITY 
 Stanford Management Company 

635 Knight Way 
 Stanford, CA 94305 

GERALD CRABTREE 
 Address

 Phone Number 
 Fax Number 

Email 
 RA CAPITAL HEALTHCARE
FUND, L.P. 
 20 Park Plaza, Suite 1200 

Boston, MA 02116 
 Attn: Rajeev Shah 

Email: rshah@racap.com 
 BLACKWELL
PARTNERS LLC—SERIES A 
 280 S. Mangum Street, Suite 210 

Durham, NC 27701 
 Attn: Jannine Lall 

Email: legal@dumac.duke.edu 
 JANUS
HENDERSON GLOBAL LIFE SCIENCES FUND and 

JANUS HENDERSON CAPITAL FUNDS PLC ON BEHALF OF
ITS SERIES JANUS HENDERSON GLOBAL LIFE SCIENCES 

c/o Janus Capital Management, LLC 
 151 Detroit Street 

Denver CO 80206 
 Attn: Legal Department, 4th Floor 

VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP 
 c/o Viking Global Investors LP 

55 Railroad Avenue 
 Greenwich, CT 06830 

Attn: General Counsel 
 Email:
legalnotices@vikingglobal.com 

Table of Contents

 PERCEPTIVE LIFE SCIENCES MASTER
FUND LTD. 
 51 Astor Place, 10th Floor 
 New
York, NY 10003 
 AISLING CAPITAL IV, L.P. 

888 Seventh Avenue, 12th Floor 
 New York, NY 10106 

Attn: Drew Schiff 
 Fax: 212 651 6379 

With a required copy to: 
 McDermott Will & Emery LLP

 340 Madison Avenue 
 New York, NY 10173-1922 

Attn: Todd Finger 
 Fax: 212 547 5444 

CORMORANT PRIVATE HEALTHCARE FUND I, LP 

200 Clarendon Street, 52nd Floor 
 Boston, MA 02116 

CORMORANT GLOBAL HEALTHCARE MASTER FUND, LP 

200 Clarendon Street, 52nd Floor 
 Boston, MA 02116 

CRMA SPV, L.P. 
 PO Box 309 

Ugland House 
 Grand Cayman 

KY1-1104 Cayman Islands 

AMZAK HEALTH INVESTORS, LLC 

980 North Federal Highway 
 Suite 315 Boca Raton 

FL 33432 
 Telephone No. 561
953-4164 
 Fax No. 561 338-7677 

Email: anders@majalincapital.com 
 Attn: Anders Hove 

Table of Contents

 SCHEDULE B 

KEY HOLDERS 
 Mamoun Alhamadsheh

 6361 Brook Hollow Circle 
 Stockton, CA 95219 

Isabella Graef 
 7 Durham Road 

Woodside, CA 94062 
 Jonathan C Fox and Suzanne Markel-Fox, 
 Co-Trustees of the Fox Family Trust 

Dated 17 Dec 2014 
 1788 Clay Street, Suite 809 

San Francisco, CA 94109 
 Christine Siu 

16 W. Santa Inez 
 San Mateo, CA 94402 

Uma Sinha 
 800 Junipero Serra Boulevard 

San Francisco, CA 94127EX-10.14

 Exhibit 10.14 

Execution Copy 
 BONUS AGREEMENT

 This bonus agreement (this “Agreement”) is entered into as of April 26, 2018 (the “Effective
Date”) by and between Eidos Therapeutics, Inc. (the “Company”) and Neil Kumar (the “Executive”). All capitalized terms set forth below and not defined shall have the respective meanings set forth in
Section 4 of this Agreement. 
 WHEREAS, the Company desires to provide the Executive with a bonus upon the occurrence of certain
events in order to induce his continued service with the Company and to encourage him to exert his very best efforts toward either the growth of the Company or the completion of a potential change in control of the Company. 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and the
Executive agree as follows: 
 1.    Bonus. In the event that following an Initial Public Offering (or the date on which the
Company’s common stock (“Common Stock”) otherwise becomes publicly-traded), either (a) the Company’s market capitalization is, following expiration of any applicable lock-up
period for the Common Stock, equal to or greater than one or more of the Valuation Thresholds set forth in the table below for any thirty (30) consecutive trading days or (b) a Change in Control occurs and the Transaction Proceeds equal or
exceed one or more of the Valuation Thresholds set forth in the table below, then the Executive shall be entitled to a lump sum cash bonus equal to the applicable Incremental Bonus set forth in the table below (each, a “Bonus”);
provided, that the Executive must remain in a continuous service relationship with the Company as its Chief Executive Officer through the date of either the events described in clause 1(a) or 1(b) (either such event, a “Trigger
Event”) in order to receive payment of a Bonus under this Agreement. 
  

					
	 Valuation Threshold*
	  	Incremental Bonus**	 
	 At least $750M
	  	$	11.25M	 
	 At least $1B
	  	$	3.75M	 
	 At least $1.25B
	  	$	3.75M	 

  

	*	Only one Bonus may be payable for each Valuation Threshold achieved. 

 Example 1:
Assuming an Initial Public Offering has occurred and the applicable lock-up period has expired, if the Company has a market capitalization of $800M on July 1, 2019 (based on thirty (30) consecutive
trading days), then the Executive shall be entitled to a Bonus equal to $11.25M. If the Company has a market capitalization of $1.1B on November 1, 2019 (based on thirty (30) consecutive trading days), then the Executive shall only be
entitled to an additional Incremental Bonus equal to $3.75M. 
 Example 2: Assuming an Initial Public Offering has occurred and the
applicable lock-up period has expired, if the Company has a market capitalization of $800M on July 1, 2019 (based on thirty (30) consecutive trading days), then the Executive shall be entitled to a
Bonus equal to $11.25M. If the Company has a Change in Control on November 1, 2019 and Transaction Proceeds from such Change in Control equal $1.2B, then the Executive shall only be entitled to an additional Incremental Bonus equal to $3.75M.

  

	**	The Executive may not receive more than $18.75M of Bonus payments, in the aggregate, under this Agreement. 

 2.    Form and Time of Bonus Payment. The Bonus shall be paid to the Executive in a
single lump sum cash payment on, or as soon as reasonably practicable following, the date of a Trigger Event, but in no event more than thirty (30) days following the applicable Trigger Event. 

3.    Tax Gross-up. 

(a)    In the event that the amount of any compensation, payment or distribution by the Company to or for the benefit of
the Executive pursuant to the terms of this Agreement, calculated in a manner consistent with Section 280G of the Internal Revenue Code of 1986, as amended (the “Code”) and the applicable regulations thereunder (the
“Aggregate Payments”), would be subject to the excise tax imposed by Section 4999 of the Code, or any interest or penalties are incurred by the Executive with respect to such excise tax (such excise tax, together with any such
interest and penalties, are hereinafter collectively referred to as the “Excise Tax”), the Executive shall be entitled to receive an additional payment or payments (collectively, the
“Gross-Up Payment”) such that the net amount retained by the Executive, after deduction of any Excise Tax on the Aggregate Payments, any federal, state, and local income tax, employment tax
and Excise Tax upon the payment provided by this Section 3(a), and any interest and/or penalties assessed with respect to such Excise Tax, shall be equal to the Aggregate Payments. 

(b)    Subject to the provisions of Section 3(c) below, all determinations required to be made under this
Section 3(b), including whether a Gross-Up Payment is required and the amount of such Gross-Up Payment, shall be made by a nationally recognized accounting firm
selected by the Company (the “Accounting Firm”), which shall provide detailed supporting calculations both to the Company and the Executive within forty-five (45) business days of the applicable Trigger Event, if applicable, or
at such earlier time as is reasonably requested by the Company or the Executive. For purposes of determining the amount of the Gross-Up Payment, the Executive shall be deemed to pay federal income taxes at the
highest marginal rate of federal income taxation applicable to individuals for the calendar year in which the Gross-Up Payment is to be made, and state and local income taxes at the highest marginal rates of
individual taxation in the state and locality of the Executive’s residence on the date of a Trigger Event, net of the maximum reduction in federal income taxes which could be obtained from deduction of such state and local taxes. The Gross-Up Payment, if any, as determined pursuant to this Section 3(b), shall be paid to the relevant tax authorities as withholding taxes on behalf of the Executive at such time or times when each Excise Tax
payment is due. Any determination by the Accounting Firm shall be binding upon the Company and the Executive. 

(c)    If, after a Gross-Up Payment by the Company on behalf of the Executive
pursuant to this Section 3, the Executive becomes entitled to receive any refund with respect to such claim, the Executive shall promptly pay to the Company the amount of such refund (together with any interest paid or credited thereon after
taxes applicable thereto). 
 4.    Definitions. 

(a)    “Change in Control” shall have the meaning for such term as set forth in the Eidos Therapeutics,
Inc. 2016 Equity Incentive Plan, as amended from time to time. 

  
 2 

 (b)    “Initial Public Offering” shall mean the consummation
of the first firm commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, covering the offer and sale by the Company of its equity securities, as a result of or following
which the stock shall be publicly held. 
 (c)    “Transaction Proceeds” means an amount equal to the
aggregate value of cash and/or property (e.g., securities, notes, etc.) paid or payable to the Company’s stockholders in connection with a Change in Control prior to any payment of a Bonus under this Agreement (all as determined by the Board of
Directors of the Company (the “Board”)). In the event that all or part of the consideration paid or payable to the Company’s stockholders in connection with a Change in Control is in the form of securities, the Transaction
Proceeds shall be deemed to include the fair market value of such securities, as determined in the sole discretion of the Board and as determined on the same basis on which such securities were valued in the transaction. 

5.    Administration. The Board shall have the sole discretionary power to administer and interpret this Agreement and make all
decisions and exercise all rights of the Company with respect to this Agreement. The Board shall have final authority to determine, in its sole discretion, the amount of a Bonus to be paid and shall also have the exclusive discretionary authority to
make all other determinations including, the determination of relevant facts, regarding the entitlement to a Bonus. All good faith decisions and interpretations by the Board hereunder are final and binding on all parties hereto. 

6.    Term. This Agreement shall take effect on the Effective Date and shall terminate upon the earliest of (a) a Change in
Control resulting in Transaction Proceeds less than $750M; (b) the date of payment to the Executive of a Bonus pursuant to clause 1(b) of this Agreement; (c) twelve (12) months following the date of payment to the Executive of an
aggregate of $18.75M, pursuant to clause 1(a) of this Agreement; (d) the termination of the Executive’s service relationship with the Company as its Chief Executive Officer; and (e) the tenth (10th) anniversary of the Effective Date. 
 7.    Withholding. Any payment made by
the Company under this Agreement shall be net of any tax or other amounts required to be withheld by the Company under applicable law. 

8.    Section 409A. The provisions regarding all payments to be made hereunder shall be interpreted in such a manner that all such
payments either comply with Section 409A of the Code or are exempt from the requirements of Section 409A of the Code as “short-term deferrals” as described in Section 409A of the Code. To the extent that any amounts payable
hereunder are determined to constitute “nonqualified deferred compensation” within the meaning of Section 409A of the Code, such amounts shall be subject to such additional rules and requirements as specified by the Board from time to
time in order to comply with Section 409A of the Code and the settlement of any such amounts may not be accelerated or delayed except to the extent permitted by Section 409A of the Code. The Company makes no representation or warranty and
shall have no liability to the Executive if any payments under any provisions of this Agreement are determined to constitute deferred compensation under Section 409A of the Code that are subject to the twenty percent (20%) tax under
Section 409A of the Code. 

  
 3 

 9.    Miscellaneous. 

(a)    Amendment. This Agreement may not be orally changed, modified or terminated, nor shall any oral waiver of any
of its terms be effective. This Agreement may be amended or modified only by a written instrument signed by the Executive and by a duly authorized representative of the Company. 

(b)    No Contract for Continuing Services. This Agreement shall not be construed as creating any contract for
continued services between the Company or any of its subsidiaries and the Executive and nothing herein contained shall give the Executive the right to be retained as an employee or other service provider of the Company or any of its subsidiaries.
Nothing in this Agreement shall change the “at will” nature of the Executive’s service to the Company 

(c)    No Transfers. The Executive’s rights in an interest under this Agreement may not be assigned or
transferred. 
 (d)    Saving Clause. If any provision(s) of this Agreement shall be determined to be illegal or
unenforceable, such determination shall in no manner affect the legality or enforceability of any other provision hereof. 

(e)    Effect on Other Plans. Nothing in this Agreement shall be construed to limit the rights of the Executive
under the Company’s benefit plans, programs or policies. 
 (f)    Obligations of Successors. In addition to
any obligations imposed by law upon any successor to the Company, the Company will use its reasonable efforts to require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the
business or assets of the Company to expressly assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform if no such succession had taken place. 

(g)    Equitable Relief. The parties hereto agree and declare that legal remedies may be inadequate to enforce the
provisions of this Agreement and that equitable relief, including specific performance and injunctive relief, may be used to enforce the provisions of this Agreement. 

(h)    Dispute Resolution. 

(i)    Except as provided below, any dispute arising out of or relating to this Agreement, or the breach, termination or
validity of this Agreement, shall be finally settled by binding arbitration conducted expeditiously in accordance with the J.A.M.S./Endispute Comprehensive Arbitration Rules and Procedures (the “J.A.M.S. Rules”). The arbitration
shall be governed by the United States Arbitration Act, 9 U.S.C. Sections 1-16, and judgment upon the award rendered by the arbitrators may be entered by any court having jurisdiction thereof. The place
of arbitration shall be the County of San Francisco. 
 (ii)    The arbitration shall commence within sixty
(60) days of the date on which a written demand for arbitration is filed by any party hereto. In connection with the arbitration proceeding, the arbitrator shall have the power to order the production of documents

  
 4 

 
by each party and any third-party witnesses. In addition, each party may take up to three (3) depositions as of right, and the arbitrator may in his or her discretion allow additional
depositions upon good cause shown by the moving party. However, the arbitrator shall not have the power to order the answering of interrogatories or the response to requests for admission. In connection with any arbitration, each party to the
arbitration shall provide to the other, no later than seven (7) business days before the date of the arbitration, the identity of all persons that may testify at the arbitration and a copy of all documents that may be introduced at the
arbitration or considered or used by a party’s witness or expert. The arbitrator’s decision and award shall be made and delivered within six (6) months of the selection of the arbitrator. The arbitrator’s decision shall set forth
a reasoned basis for any award of damages or finding of liability. The arbitrator shall not have power to award damages in excess of actual compensatory damages and shall not multiply actual damages or award punitive damages, and each party hereby
irrevocably waives any claim to such damages. 
 (iii)    Each party to this Agreement covenants and agrees that such
party will participate in the arbitration in good faith. This Section 9(h) applies equally to requests for temporary, preliminary or permanent injunctive relief, except that in the case of temporary or preliminary injunctive relief any party
may proceed in court without prior arbitration for the limited purpose of avoiding immediate and irreparable harm. 

(iv)    Each party to this Agreement (A) hereby irrevocably submits to the jurisdiction of any United States District
Court of competent jurisdiction for the purpose of enforcing the award or decision in any such proceeding, (B) hereby waives, and agrees not to assert, by way of motion, as a defense, or otherwise, in any such suit, action or proceeding, any
claim that it is not subject personally to the jurisdiction of the above named courts, that its property is exempt or immune from attachment or execution (except as protected by applicable law), that the suit, action or proceeding is brought in an
inconvenient forum, that the venue of the suit, action or proceeding is improper or that this Agreement or the subject matter hereof may not be enforced in or by such court, and (C) hereby waives and agrees not to seek any review by any court
of any other jurisdiction which may be called upon to grant an enforcement of the judgment of any such court. Each party to this Agreement hereby consents to service of process by registered mail at the address to which notices are to be given. Each
party to this Agreement agrees that its, his or her submission to jurisdiction and its, his or her consent to service of process by mail is made for the express benefit of each other party. Final judgment against any party to this Agreement in any
such action, suit or proceeding may be enforced in other jurisdictions by suit, action or proceeding on the judgment, or in any other manner provided by or pursuant to the laws of such other jurisdiction. 

(i)    Headings. The headings are intended only for convenience in finding the subject matter and do not constitute
part of the text of this Agreement and shall not be considered in the interpretation of this Agreement. 

(j)    Counterparts. For the convenience of the parties to this Agreement and to facilitate execution, this
Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which shall constitute one and the same document. 

  
 5 

 (k)    Governing Law. This Agreement shall be construed in accordance
with and governed by the laws of the State of California, without regard to principles of conflict of laws of such state. 
 [SIGNATURE PAGE
IMMEDIATELY FOLLOWS] 

  
 6 

 IN WITNESS WHEREOF, the parties have duly executed this Agreement as of the Effective Date first
written above. 
  

			
	EIDOS THEREAPEUTICS, INC.
		
	By:	 	/s/ Eric Aguiar
	Name:	 	Eric Aguiar
	Title:	 	Director

  

	
	EXECUTIVE:
	
	/s/ Neil Kumar
	Neil Kumar

  
 7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00284-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00284-of-00352.parquet"}]]